Advanced Oncotherapy Share Discussion Threads

[someuwin] 31/5/2016 11:01

Lots of good info and pictures in the annual report...

[haydock] 31/5/2016 09:53

Managing the share price
Usually a good idea:
Penny shares are often seen as poisonous.

SHARE CONSOLIDATION

The Company currently has 1,418,342,375 ordinary shares in issue and we will be seeking approval from shareholders at the upcoming Annual General Meeting to reduce this number through a consolidation of every 25 existing ordinary shares into one new consolidated ordinary share. We believe this will lead to the Company having a more readily understood share price and number of shares in issue. Further details of this are set out in the Directors Report included in the Annual Report and notice of Annual General Meeting.

[jimbobjames2002] 31/5/2016 09:51

"The Company currently has 1,418,342,375 ordinary shares in issue and we will be seeking approval from shareholders at the upcoming Annual General Meeting to reduce this number through a consolidation of every 25 existing ordinary shares into one new consolidated ordinary share. We believe this will lead to the Company having a more readily understood share price and number of shares in issue."

So I presume based on the current share price of 7.69p, AVO would be 25x this at 192.25p with 56,733,695 shares in issue?

[waterloo01] 31/5/2016 08:07

Anyone any clearer on when Harley St might be open (let alone work started on the buildings?)

[werty5] 31/5/2016 07:44

Yep not much new in the statement but a steady ship. I liked the bit about the continued testing and how they are pleased with the results so far, that is about as much new infomation i could pick off the bones.

[someuwin] 31/5/2016 07:29

All seems to be on track.

[luminoso] 27/5/2016 13:59

If you just change the h of http to a capital H, the link will post in an instantly clickable form and get round the censor !

[daijavu] 27/5/2016 13:54

Just join the two bits together for the full link

[daijavu] 27/5/2016 13:53

I tried to post the link to: proactiveinvestor.co.uk

/companies/news/126485/advanced-oncotherapy-hadron-collider-to-harley-street-126485.html

[daijavu] 27/5/2016 13:50

Another article today:

[...]

[someuwin] 27/5/2016 09:23

SP still below the level it was a year ago despite significant progress on product, manufacturing, and corporate fronts.

[daijavu] 27/5/2016 09:21

Thanks someuwin. Got it now.

[luminoso] 27/5/2016 09:12

600k trade is interesting. Buy ?

[luminoso] 27/5/2016 08:51

altom

You can edit your post after posting it. Click on "edit' which appears next to one of your own posts and then you can delete sections of the post, add anything, correct spelling, whatever, and then click 'update' to repost the edited post on the board.

[someuwin] 27/5/2016 08:36

Beaufort link...

[daijavu] 27/5/2016 08:26

Thanks for the beaufort article, someuwin. Could you give us the link please?

[altom] 27/5/2016 08:14

someuwin.
a} Don't know how.
b} Thank you very much for Beaufort comment.

werty5.
Thank you very much indeed. Kind of you to take the time.

altom.

[someuwin] 27/5/2016 07:55

Beaufort comment...

Advanced Oncotherapy (AVO.L, 7.50p) - Speculative Buy
Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, yesterday announced that it has signed an agreement with a fund advised by Metric Capital Partners LLP, a pan-European private capital fund manager, whereby Metric Capital will invest £24 million in a financing facility to support AVO's provision of vendor financing for the installation of the Group's first LIGHT machine in Harley Street. Funding for this clinic, the London Proton Therapy Centre Limited, will come from AVO and its partners in equal amounts in the form of equity totaling £6 million plus the provision of a vendor loan arranged by Advanced Oncotherapy to LPTC. The Agreement is subject to customary representations and undertakings. AVO will pay a cash interest of 250 basis points per annum above 3 month LIBOR (subject to a minimum LIBOR of 150 basis points) payable quarterly and payment in kind ('PIK') interest of 850 basis points payable at maturity or convertible into ordinary Advanced Oncotherapy shares at 10p per Ordinary Share (subject to customary adjustments for convertible instruments). In addition, the Company has agreed to issue to Metric Capital each year during the life of the Agreement warrants over 14.5 million Ordinary Shares exercisable at 16p per Ordinary Share. The Agreement has a term of 5 years and requires any future equity capital injections to be carried out on terms similar to or better than the conversion rights of the PIK interest described above. Of the £24 million financing, £11 million will be received shortly following signing. The second tranche of £13 million will be available for drawdown on completion of a £25 million cash or capital injection to fund the development of a manufacturing base. Should these milestones not be achieved by the end of March 2017, the initial £11 million tranche will become repayable by September 2017. Metric Capital will have the right to consent to certain reserved matters and the right to appoint a director to the Board of both Advanced Oncotherapy and LPTC and, in certain circumstances ADAM SA, a wholly owned subsidiary of Advanced Oncotherapy.

Our view: This is significant and important news for AVO. Not only does it tell us that a senior institutional lender has taken a very close look at the Group and concluded that LIGHT is viable and that its expect its first installation in Harley Street to rapidly become capable of generating strong cash flow, but also that AVO is both sufficiently confident and advanced in its planning to establish a general provision of vendor financing for its prospective international customers. Such proton beam centre financing routes are already routinely used by first generation suppliers to provide the facilities demanded by hospitals and medical practitioners around the globe, so in this respect this is a natural step forward. Moreover, given that AVO is sticking rigidly to its development schedule, whereby the first commercial sales of LIGHT should begin in 2017 whereafter they are expected ramp up in response to significant demand, this facility is likely to become actively used. As has been explained in numerous research documents, Beaufort's commercial scenario for LIGHT is that the cost, safely, operational and size advantages its brings to the world of proton therapy, will effectively render 'first generation' systems all but obsolete; its development will also very significantly expand the international market for such systems from some US$2.5bn annually right now, to a figure potentially ten-times as large as LIGHT becomes the obvious successor to the similarly-priced but now relatively antiquated X-ray radiation systems that have a global installed base in excess of 20,000 units. In this respect, LIGHT uniquely faces a giant and accelerating global opportunity. Beaufort remains a very enthusiastic supporter of Advanced Oncotherapy and repeats its Speculative Buy recommendation on the shares.

[werty5] 27/5/2016 07:54

Hi Altom, two ways of following the link. 1st the old fashion way write the link down on paper and then type into your web browser bar. 2nd bring the computer cursor up to the start of the link just before the http and left click your mouse button, keeping the button held down run the cursor over the whole link until it has been highlighted, once highlighted right click on your mouse and select the copy command. Now that is done if you put your cursor up into the web browser bar and right click again and select paste followed by the enter key on your keyboard that should take you to the site. Good luck.

[someuwin] 27/5/2016 07:29

...Why not just edit your post and remove the paragraph?

[altom] 27/5/2016 07:24

Please ignore my last paragraph. WRONG COMPANY. Sorry

[altom] 27/5/2016 07:22

could someone please explain in very simple language how to open the Evening Standard article ?
I also think that the BoD is doing a very good job, but their handling of the Harley St. planning application delay was poor. This information should have been made public several weeks sooner. It was only when I and several other PI's contacted the company that an RNS appeared next day. Poor judgement by the company and it's financial PR advisers.
I look forward to the announcement on funding with great interest. I have taken some profits but keeping cash available to buy again after funding announcement.
I am guessing the share price will drop appreciably.

[twirl] 26/5/2016 18:02

You're welcome freddythefish.

Thanks for spotting the Evening Standard article trustmeimastomach and thanks for the link werty5 - should raise awareness.

[werty5] 26/5/2016 17:16

Link to evening standard article.http://www.standard.co.uk/business/harley-street-cancer-firm-advanced-oncotherapy-gets-24m-boost-a3257621.html